![](/img/cover-not-exists.png)
[BMJ Publishing Group Ltd and European League Against Rheumatism Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12â15 June 2019 - ()] SATURDAY, 15 JUNE 2019 - SAT0166â GOLIMUMAB AS FIRST, SECOND OR AT LEAST THIRD BIOLOGIC AGENT IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA), PSORIATIC ARTHRITIS (PSA) OR ANKYLOSING SPONDYLITIS (AS) â POST HOC ANALYSIS OF A NON-INTERVENTIONAL STUDY IN GERMANY
Krueger, Klaus, Burmester, Gerd Rüdiger, Wassenberg, Siegfried, Thiele, Astrid, Thomas, MatthiasYear:
2019
DOI:
10.1136/annrheumdis-2019-eular.3245
File:
PDF, 372 KB
2019